Navigation Links
RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments
Date:1/13/2009

stimated," "anticipated," or similar expressions, or by express or implied discussions regarding potential regulatory filings or marketing approvals for RAD001 or regarding potential future revenues from RAD001. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with RAD001 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that RAD001 will be approved for sale for any oncology indication in any market. Nor can there be any guarantee that RAD001 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding RAD001 could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this pre
'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
2. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
3. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
4. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
5. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
6. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
7. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... March 31, 2015 Point-of-Care Partners, a ... consulting firm, has launched the ePA State Navigator ... IT vendors, payers and pharmacies to quickly assess ... authorization (ePA) of prescription medications. Today, ... are completed through time-consuming, manual processes amongst prescribers, ...
(Date:3/31/2015)... ROCHELLE, N.Y. , March 31, 2015 /PRNewswire-USNewswire/ ... it will be featured in the American Medical ... by ITN Productions. AMGA,s "High Performing ... on the challenges facing the nation,s healthcare system ... Medical Letter is profiled along with other leading ...
(Date:3/31/2015)... March 31, 2015 RnRMarketResearch.com ... market research report of 68 pages with latest ... intelligence library. The report "Pemphigus - Pipeline Review, ... therapeutic development for Pemphigus , complete with ... drug target, mechanism of action (MoA), route of ...
Breaking Medicine Technology:Point-of-Care Partners Launches the ePA State Navigator 2AMGA's High Performing Health News Program Features The Medical Letter 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 3Pemphigus Therapeutic Development and Pipeline Review H1 2015 4
... , , ... Inc.,("Chindex") (Nasdaq: CHDX ), a leading independent American provider of ... that the Company will attend the 21st Annual Piper Jaffray,"Unplugged" Health ... the,New York Palace Hotel. , Management is ...
... SAN DIEGO, Nov. 24 Anadys Pharmaceuticals, Inc. (Nasdaq: ... 21st Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, ... conference is being held at The New York Palace Hotel. ... Anadys, will provide an overview of Anadys and its clinical ...
Cached Medicine Technology:Chindex International to Present at Piper Jaffray Health Care Conference 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2
(Date:4/1/2015)... Results are in for the fifth annual ... homes from across the state exemplifying high-efficiency design. Participants ... techniques and new technology intended to lower energy use ... provided sustainability consulting services for 4 of the 11 ... and third-place winners. , The Benker Residence, a four-bedroom ...
(Date:4/1/2015)... 01, 2015 Poisonous plants (poison ivy, ... change in recent years, increasing significantly in number and ... if exposed to poison plants (according to the American ... prepare for summer adventures in nature, they should be ... reaction is greater than ever. This year, Ivarest adds ...
(Date:3/31/2015)... 2015 Bon Secours New York Health ... Schervier Nursing Care Center family last week. The Sisters ... in Yonkers which is scheduled to close later this ... of the Sisters of Charity of New York, the ... to place their Sisters at Schervier Nursing Care Center ...
(Date:3/31/2015)... 2015 As the demand for optimized ... to have a mobile-friendly website online sometime during the ... Chunk Fitness’ continued commitment to bring the best and ... All of the same great fitness information at ... substantially easier to read while browsing on a mobile ...
(Date:3/31/2015)... Dr. Parsa Mohebi, founder of Parsa Mohebi Hair Restoration has been ... using beard hair to fill in balding areas on ... now become an absolute option for giving patients the best results ... that beard to scalp hair transplant can be a patients best ... dense as we would like it,” says Dr. Parsa Mohebi. , ...
Breaking Medicine News(10 mins):Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 2Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 3Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 4Health News:New Ivarest Poison Ivy Itch Spray Provides All-Day Comfort 2Health News:Bon Secours New York Health System Welcomes Retired Sisters of Charity to the Family 2Health News:Is Beard to Scalp Hair Transplant the Future? 2
... The National Heart, Lung, and Blood Institute (NHLBI) of ... trial testing a drug treatment for pulmonary hypertension in ... due to safety concerns. In an interim review of ... of treatment, researchers found that, compared to participants on ...
... N.Y. -- A new study by psychologists at the ... of Engineering finds that in the aftermath of national ... happened has implications for individual well-being and that the ... very different psychological outcomes for them. The study, "The ...
... hospitalization in study , TUESDAY, July 28 (HealthDay News) ... risk of ending up in the hospital with elevated blood ... more seniors are being prescribed these medications for dementia and ... the July 27 issue of Archives of Internal Medicine ...
... says real change begins with America,s kids, , TUESDAY, July ... carries the hefty price tag of $147 billion per year ... medical spending, experts reported at a national conference Tuesday in ... American Cancer Society estimates that all cancers combined cost our ...
... NASDAQ: CRME TSX: COM, , , ... / TSX: COM) today announced that it has earned a ... Co., Inc., through an affiliate. The milestone was triggered ... (MAA) to the European Medicines Agency (EMEA) seeking marketing approval ...
... , , , ST. ... ground-level ozone, microscopic particle pollution like smoke and smog, as ... sensitive to these airborne contaminants to experience shortness of breath, ... cause lung irritation(1). According to AIRNow.gov(2), a government-developed index for ...
Cached Medicine News:Health News:NHLBI stops study of pulmonary hypertension treatment in sickle cell patients 2Health News:NHLBI stops study of pulmonary hypertension treatment in sickle cell patients 3Health News:NHLBI stops study of pulmonary hypertension treatment in sickle cell patients 4Health News:NHLBI stops study of pulmonary hypertension treatment in sickle cell patients 5Health News:Stories we tell about national trauma reflect our psychological well-being 2Health News:Stories we tell about national trauma reflect our psychological well-being 3Health News:Older Diabetics Should Avoid Dementia Meds 2Health News:More Can Be Done to Slow Obesity's Toll on Health: Experts 2Health News:More Can Be Done to Slow Obesity's Toll on Health: Experts 3Health News:More Can Be Done to Slow Obesity's Toll on Health: Experts 4Health News:Cardiome Achieves Milestone From Collaboration With Merck Co., Inc. 2Health News:Cardiome Achieves Milestone From Collaboration With Merck Co., Inc. 3Health News:Bad Air Day Alert: Outdoor Air Pollutants at High Level 2Health News:Bad Air Day Alert: Outdoor Air Pollutants at High Level 3
... manipulation and removal in the ... wire allows the basket to ... torsion. The unique tipless design ... damage and perforation. Supplied sterile ...
Used to negotiate spiral folds of the cystic duct and the lumen of the common duct. TFE coating reduces surface tension. Supplied sterile in peel-open packages. Intended for one-time use....
Used for internal biliary drainage. Supplied sterile in peel-open packages. Intended for one-time use....
... cholangiography and bile stone ... lumen catheter design allows ... and wire basket placement ... sterile in peel-open packages. ...
Medicine Products: